1983
Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer
Johnston‐Early A, Cohen M, Fossieck B, Harwood S, Ihde D, Bunn P, Matthews M, Minna J, Makuch R. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983, 52: 1395-1400. PMID: 6311393, DOI: 10.1002/1097-0142(19831015)52:8<1395::aid-cncr2820520810>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Small CellFemaleHumansHypersensitivity, DelayedLung NeoplasmsMaleMiddle AgedProbabilityPrognosisProspective StudiesSkin TestsConceptsSkin test reactivityGood performance statusLow tumor burdenTest reactivityAnergic patientsPerformance statusTumor burdenReactive patientsSmall cell lung cancer patientsHypersensitivity skin test reactivityCell lung cancer patientsSmall cell lung cancerGood prognosis patientsHypersensitivity skin testingCell lung cancerLung cancer patientsSkin test antigensPrognosis patientsSkin testingPoor prognosisPrognostic importancePrognostic utilityPrognostic indicatorCancer patientsLung cancer
1980
Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity
Baskies A, Chretien P, Weiss J, Makuch R, Beveridge R, Catalona W, Spiegel H. Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 1980, 45: 3050-3060. PMID: 7388749, DOI: 10.1002/1097-0142(19800615)45:12<3050::aid-cncr2820451229>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsDepressed cellular immunityLymphocyte reactivityCellular immunityCancer patientsAlpha 2 HS-glycoproteinAlbumin levelsTumor extentHS-glycoproteinVivo parametersLevels of haptoglobinLevels of APPSerum glycoprotein levelsSerum protein levelsSerum glycoproteinsOngoing trialsPreoperative patientsRegional tumorsSerum levelsImmune statusImmunologic functionSolid malignanciesNormal controlsPatientsGlycoprotein levelsPrimary site